Injectafer

Ferric Carboxymaltose, the active ingredient in Injectafer, is an iron preparation presented as an injectable solution for intravenous use. It treats iron deficiency anemia, primarily in adults who require rapid iron repletion, such as those with chronic kidney disease, gastrointestinal blood loss, or intolerance to oral iron.

GNH USA supplies Injectafer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Injectafer is an intravenous iron formulation used to correct iron deficiency anemia across several clinical settings.

- Iron deficiency anemia: restores depleted iron stores and raises hemoglobin levels. - Chronic kidney disease‑associated anemia: provides rapid iron repletion when oral iron is ineffective. - Inflammatory bowel disease‑related iron deficiency: corrects anemia caused by malabsorption. - Pre‑operative anemia: improves hemoglobin before surgery to reduce transfusion risk.

Injectafer may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient feeling of stomach upset. - Headache: mild to moderate intensity. - Injection site pain: localized discomfort at the infusion site. - Transient hypotension: brief drop in blood pressure during or shortly after infusion. - Metallic taste: brief alteration in taste perception.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decline that may need intervention. - Hypersensitivity reactions: rash, urticaria, or bronchospasm. - Iron overload: excessive iron accumulation with potential organ damage. - Acute respiratory distress: sudden breathing difficulty. - Myocardial infarction: rare cardiac event linked to rapid iron release.

Injectafer should be used with careful clinical assessment and monitoring.

- Assess iron status: confirm iron deficiency before initiating therapy. - Monitor hematology: check hemoglobin and ferritin levels during treatment. - Hypersensitivity caution: avoid in patients with known severe reactions to IV iron. - Infusion rate control: administer at recommended rate to reduce hypotension risk. - Infection consideration: evaluate active infections before use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Injectafer can interact with other agents that affect iron metabolism or cause additive adverse effects.

Major Interactions (Avoid): - Concurrent IV iron products: may cause iron overload. - Known hypersensitivity to dextran or other iron complexes: risk of severe allergic reaction. - High‑dose vitamin C administered intravenously: can increase free iron and toxicity.

Moderate Interactions (Monitor Closely): - Oral iron supplements taken simultaneously: may reduce absorption of each other. - Antacids containing aluminum or magnesium: can interfere with iron availability. - Tetracycline antibiotics: may chelate iron and diminish antibiotic efficacy.